Laresin Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil blocks the AT1 subtype of angiotensin II receptors. By preventing angiotensin II from binding, it inhibits vasoconstriction, aldosterone release, and sodium retention, leading to relaxed blood vessels and reduced fluid overload, which together lower arterial pressure.

The dose of Laresin Plus is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. The prescriber determines the appropriate strength and dosing schedule; patients should follow the written prescription exactly.

The safety of Laresin Plus in pregnancy has not been established, and the product is generally avoided unless the potential benefit outweighs the risk. Limited data are available for breastfeeding; therefore, clinicians usually recommend alternative therapies for pregnant or nursing mothers.

To request Laresin Plus, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent therapies, Laresin Plus offers dual action: an ARB for vascular relaxation and a thiazide diuretic for volume reduction. This combination often achieves blood‑pressure control more efficiently than monotherapy, while maintaining a safety profile similar to each component used alone.

Store Laresin Plus at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure the container is tightly closed to maintain product stability.

Laresin Plus is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush, chew, or split the tablet unless specifically instructed.

Patients should be alert for signs of severe allergic reaction (rash, swelling, difficulty breathing), angioedema, marked drops in blood pressure causing dizziness or fainting, significant electrolyte disturbances (especially high potassium), and sudden worsening of kidney function. Any of these symptoms require immediate medical attention.

Laresin Plus is contraindicated in individuals with known hypersensitivity to olmesartan, hydrochlorothiazide, or any tablet components. It should also be avoided in patients with severe renal impairment, hyperkalemia, or those taking prohibited medications such as other ARBs, ACE inhibitors, or potassium‑sparing diuretics without close supervision.